- Eyenovia closes $50 million private placement to acquire HYPE tokens.
- Plans to rebrand as Hyperion DeFi, maintaining focus on Optejet UFD development.
- FDA registration for Optejet UFD is on track for September 2025.
Eyenovia, Inc. (EYEN, Financial), a notable player in the ophthalmic technologies industry, has completed a $50 million private placement aimed at establishing a cryptocurrency treasury reserve. This enabled the acquisition of 1,040,584.5 HYPE tokens at an average price of approximately $34 per token. This move marks Eyenovia as the first Nasdaq-listed company to run a validator on the Hyperliquid blockchain, a layer one blockchain optimized for high-frequency trading.
In conjunction with this strategic cryptocurrency investment, Eyenovia has announced plans to rebrand itself as Hyperion DeFi with a new ticker symbol, HYPD. Despite this shift, the company remains dedicated to its core ophthalmic technology. The ongoing development of its proprietary Optejet User Filled Device (UFD) remains on schedule, with FDA registration anticipated in September 2025. Verification and validation activities are set to commence next month, ensuring the company is on track with its projected timeline.
Eyenovia's dual approach involves engaging in discussions with several potential partners for licensing its Optejet platform, primarily focusing on over-the-counter applications such as lens rewetting and artificial tears. By maintaining focus on both digital currency and medical device innovation, Eyenovia continues to broaden its strategic horizons, aiming to provide retail and institutional investors with secure access to the Hyperliquid ecosystem, while progressing its biomedical advancements.
